Ciliary neurotrophic factor (CNTF) associates with an ␣ subunit (CNTFR␣) of the receptor complex to initiate signal transduction by facilitating heterodimerization of the gp130 transducing protein and the leukemia inhibitory factor receptor (LIFR) ␤. CNTFR␣ is anchored to the membrane by a glycosylphosphatidylinositol linkage; however, a soluble form of the ␣ subunit can still bind CNTF to recruit the signal transducing components of the receptor complex. In the present study we show that alanine substitution for residues Thr 268 and Asp 269 of the CNTFR␣ subunit results in a mutated receptor subunit (R3), which can bind CNTF with an affinity similar to that of the wild type CNTFR␣ but, when expressed as a soluble receptor subunit, lowers the binding of CNTF to its tripartite receptor. In addition, CNTFR3␣ inhibits the proliferation of the TF1 hematopoietic cell line triggered by CNTF plus soluble wild type CNTFR␣ but not by IL-6 or oncostatin M. Similarly, CNTFR3␣ specifically antagonizes the induction of gp130 and LIFR␤ tyrosine phosphorylation observed in response to CNTF and wild type soluble CNTFR␣ in the HepG2 hepatoma cell line, as well as the subsequent events leading to haptoglobin synthesis. Positions 268 and 269 of CNTFR␣ appear to be critical for its interaction with gp130 and LIFR␤, whereby alanine substitution of the residues at these positions results in antagonism of the CNTF-induced response.
Ciliary neurotrophic factor (CNTF) associates with an ␣ subunit (CNTFR␣) of the receptor complex to initiate signal transduction by facilitating heterodimerization of the gp130 transducing protein and the leukemia inhibitory factor receptor (LIFR) ␤. CNTFR␣ is anchored to the membrane by a glycosylphosphatidylinositol linkage; however, a soluble form of the ␣ subunit can still bind CNTF to recruit the signal transducing components of the receptor complex. In the present study we show that alanine substitution for residues Thr 268 and Asp 269 of the CNTFR␣ subunit results in a mutated receptor subunit (R3), which can bind CNTF with an affinity similar to that of the wild type CNTFR␣ but, when expressed as a soluble receptor subunit, lowers the binding of CNTF to its tripartite receptor. In addition, CNTFR3␣ inhibits the proliferation of the TF1 hematopoietic cell line triggered by CNTF plus soluble wild type CNTFR␣ but not by IL-6 or oncostatin M. Similarly, CNTFR3␣ specifically antagonizes the induction of gp130 and LIFR␤ tyrosine phosphorylation observed in response to CNTF and wild type soluble CNTFR␣ in the HepG2 hepatoma cell line, as well as the subsequent events leading to haptoglobin synthesis. Positions 268 and 269 of CNTFR␣ appear to be critical for its interaction with gp130 and LIFR␤, whereby alanine substitution of the residues at these positions results in antagonism of the CNTF-induced response.
Ciliary neurotrophic factor (CNTF) 1 was originally identified as a promoter of parasympathetic motor neuron survival in embryonic chick ciliary ganglion (Adler et al., 1979; Stockli et al., 1989) . Additional biological activities have been ascribed to CNTF, and it has been shown to act on several neuronal populations including peripheral sensory neurons, sympathetic neurons, and spinal motoneurons (Barbin et al., 1984; Ernsberger et al., 1989; Sendtner et al., 1990; Martinou et al., 1992) . CNTF displays non-neuronal activity, whereby it is able to maintain embryonic stem cells in an undifferentiated state (Conover et al., 1993) . It also exerts an effect on skeletal muscle, whereby CNTF increases muscle strength in adult mice (Helgren et al., 1994) . CNTF is a regulator of the glial response to neural lesions, and elevated CNTF levels in transgenic mice were associated with a reactive gliosis that is often observed in cases of central nervous system injury and disease (Norton et al., 1992; Eddelston and Mucke, 1993; Winter et al., 1995) .
CNTF belongs to the IL-6 cytokine family that also includes leukemia inhibitory factor (LIF), IL-11, oncostatin M (OSM), and cardiotrophin-1 (Lin et al., 1989; Stockli et al., 1989; Kishimoto et al., 1995; Pennica et al. 1995a) . Redundant activities of these cytokines are in part explained by the nature of their receptors, all of them utilizing a gp130 component that was first characterized as the IL-6 subunit transducer (Taga et al., 1989; Hibi et al., 1990; Gearing et al., 1992; Davis et al., 1993a; Yin et al., 1993; Pennica et al., 1995b) . In addition, LIF, cardiotrophin-1, OSM, and CNTF utilize a second transducing receptor component known as gp190 or LIF receptor ␤ (LIFR␤), which was initially isolated as the LIF-binding subunit (Gearing et al., 1991 (Gearing et al., , 1992 (Gearing et al., , 1994 Davis et al., 1993a; Pennica et al., 1995b) . CNTF binding specificity is determined by a third additional subunit (CNTFR␣), which contributes to the formation of the high affinity tripartite CNTF receptor (Davis et al., 1991 (Davis et al., , 1993a Gearing et al., 1994) . CNTFR␣ lacks a cytoplasmic domain, although it is anchored to the membrane by a glycosylphosphatidylinositol linkage (Davis et al., 1991) . In contrast to gp130 or LIFR␤, CNTFR␣ does not appear to play a role in signal transduction. Indeed, the function of CNTFR␣ subunit is to increase CNTF affinity for the transducing receptor complex. In addition, it was reported that a soluble form of CNTFR␣ (lacking the glycosylphosphatidylinositol linkage) can bind CNTF and activate gp130-LIFR␤-bearing cells (Taga et al., 1992; Davis et al., 1993b; Robledo et al., 1996) . Binding of CNTF to its trimeric receptor leads to the dimerization of the two ␤ transducing subunits, gp130 and LIFR␤, followed by activation of intracellular Jak/Tyk tyrosine kinases . Subsequently, the signal is relayed to the nucleus by a family of transcription factors known as STATs (signal transducers and activators of transcription), which are activated in the cytoplasm prior to their translocation into the nucleus (reviewed in Ihle and MacKerr (1995) ; Stahl et al. (1995) ; Boulton et al. (1995) ). Furthermore, the mitogen-activated protein kinase pathway has been implicated in the CNTF-induced transduction signal .
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CNTFR␣ shows 50 and 54% homology with the IL-6 receptor ␣ (IL-6R␣) and with the IL-11 receptor ␣ (IL-11R␣), respectively (Yamasaki et al., 1988; Hilton et al., 1994; Cherel et al., 1995) . Two regions of the IL-6R␣ involved in its association with gp130 are conserved in the IL-11 and CNTF receptor ␣ subunits. Hence, these two regions might be implicated in the interaction of these binding subunits (IL-11R␣, CNTFR␣) with gp130 or the LIFR␤ (Yawata et al., 1993; Salvati et al., 1995) .
In order to further investigate the role of the conserved regions within the three different types of ␣ subunit, the corresponding regions in the CNTFR␣ were mutated, and the translation product was compared with the wild type CNTFR␣ protein. The results are consistent with observations for the IL-6R␣, whereby the equivalent portion(s) of CNTFR␣ appear essential for its interaction with the transducing subunits of the receptor complex. Moreover, the present study demonstrates that a mutated soluble CNTFR␣ subunit is still able to bind CNTF but specifically antagonizes signal transduction of the receptor complex, gene transcription, and the proliferative response to CNTF.
MATERIALS AND METHODS
Site-directed Mutagenesis of CNTFR␣-The cDNA encoding CNTFR␣ was kindly provided by G. D. Yancopoulos (Regeneron, Tarrytown, NY) and was subcloned into the HindIII/NotI sites of the pCDNA1/Amp expression vector (In Vitrogen, San Diego, CA). Ligated products were transfected into the CJ 236 strain of bacteria, and single strand DNAs were obtained after co-infection with M13 helper phage (M13KO7 from Pharmacia, Uppsala, Sweden). Mutated DNAs were generated by using the method developed by Kunkel et al. (1987) (DNA sequences can be communicated upon request). Truncated soluble CNTFR␣ was generated by adding a stop codon at position 1346 by polymerase chain reaction. Mutations identical to those performed for the membrane-anchored receptor were introduced by the Kunkel method. Mutations were verified by DNA sequencing using the T7 sequencing kit from Pharmacia.
Cytokines-Rat CNTF (2.5 ϫ 10 6 units/mg) was produced as a glutathione S-transferase fusion protein by using the pGEX-4T2 gene fusion vector from Pharmacia. Human LIF (10 8 units/mg) was immunopurified from the conditioned medium of Chinese hamster ovary cells, which stably secretes the recombinant protein, as provided by Dr. K. Turner (Genetics Institute, Cambridge, MA). IL-6 (10 7 units/mg) and OSM (2 ϫ 10 6 units/mg) were purchased from Peprotech (Canton, MA).
Production and Quantification of the Soluble CNTFR␣ Subunit-Mutated cDNAs of CNTFR␣ were transfected into the COS-7 cell line by using the DEAE-dextran method. Supernatants were harvested, and soluble receptors were partially purified by using concanavalin A-Sepharose beads (Pharmacia). Soluble CNTF receptors were quantified by ELISA. 10 g/ml polyclonal antibody raised against soluble CNTFR␣ was coated for 6 h in 100 mM carbonate, pH 9.6. Samples were mixed in a 1:1 ratio with phosphate-buffered saline, 0.1% bovine serum albumin containing 150 ng/ml biotinylated soluble CNTFR␣ and added in duplicate to the plate previously saturated with 100 mM Tris-HCl, pH 7.8, containing 20% sucrose. After overnight incubation, streptavidin peroxidase (Dako, Glostrup, Denmark) was added at a 1:10,000 dilution for a 1-h incubation. ABTS (Sigma, l'Isle d'Abeau Chesnes, France) was used as substrate, and the absorbance was recorded at 405 nm.
CNTF Radiolabeling and Binding Experiments-CNTF was iodinated using the two-phase method as described previously . Specific radioactivity was 75,000 -125,000 cpm/ng, and the radiolabeled samples remained stable for more than 2 weeks. CNTF binding experiments were carried out as described previously .
Bioassays-A TF-1 cell proliferation assay was performed as described previously (Davis et al., 1993b; Fourcin et al., 1994) . Briefly, serial dilutions of soluble mutated CNTFR␣ were added to 10 4 TF-1 cells in triplicate in the presence of a fixed concentration of CNTF (5 ng/ml). For the R3 antagonist assay, fixed amounts of CNTFR3 (300 ng/ml) and CNTFR␣ (30 ng/ml) were mixed with serial dilutions of cytokines and added to the TF-1 cells. Cells were then incubated for 72 h before being pulsed with 0.5 Ci of [ 3 H]thymidine (Amersham, Les Ullis, France) for the last 4 h of the culture. Incorporated radioactivity was determined by using a ␤-counter. HepG2 hepatoma cells were plated in triplicate in 96-well plates at a concentration of 50 ϫ 10 3 cells/well in 200 l of RPMI medium containing 10% fetal calf serum, 10 Ϫ6 M dexamethasone, and the indicated concentrations of CNTF, LIF, or soluble CNTFR␣. After 20 h, the supernatants were harvested, and their haptoglobin content was determined by ELISA .
gp130 and gp190-LIFR␤ Tyrosine Phosphorylation Assay-HepG2 cells were starved for 4 -6 h in RPMI medium and stimulated with the indicated combination of CNTF (50 ng/ml), LIF (50 ng/ml), CNTFR␣ (500 or 5,000 ng/ml), and CNTFR3 (5,000 ng/ml) (Fourcin et al., 1994) . After a 10-min activation, cells were lysed, and the samples were analyzed as described previously .
RESULTS

CNTFR␣ Mutagenesis, Expression, and Binding of Radiolabeled CNTF-Amino acids His 280 and Asp 281 of the IL-6R␣
were previously reported to be implicated in the interaction between IL-6R␣ and gp130 (Yawata et al., 1993; Salvati et al., 1995) . These two amino acids are part of the E2 strand of the second barrel of the cytokine binding domain as defined by Bazan (Bazan, 1990) . Based on the alignment of IL-6R␣ and CNTFR␣, a series of CNTFR␣ mutants was derived by substituting Ala or Asn for the amino acids corresponding to the defined areas of IL-6R␣ interacting with gp130, as indicated in Fig. 1A . One additional Val residue located at position 190 and belonging to the F1 strand of the IL-6R␣ was also shown to be involved in the association of the IL-6 binding component with gp130. Its equivalent in CNTFR␣ was substituted by a Gly residue. Mutated receptors were first constructed to generate surface proteins anchored to the membrane. To assess their CNTF binding capacities the cDNAs were transfected into the COS-7 cell line, and binding experiments were carried out by using 125 I-CNTF ( Fig. 1B) . When expressed alone, wild type (WT) CNTFR␣ bound the neurotrophic factor with a low affinity (K d ϭ 2-3 nM), in agreement with previously published studies (Gearing et al., 1994; Wong et al., 1995 . A similar range of affinity binding was observed for all generated mutants, indicating that the introduced amino acid substitutions did not significantly perturb the ligand/receptor interaction. With the exception of the R2 mutant, whose expression level was slightly lowered, the number of binding sites detected at the surface of COS-7 cells was similar to that observed for the WT CNTFR␣.
Production and Quantification of Soluble Mutated Receptors-In order to analyze the functionality and the interactions of the mutated receptors with the transducing subunits, the proteins were expressed as soluble products. To perform these experiments the cDNA encoding for CNTFR␣ was truncated at position 1346 by introducing a stop codon and further mutated as described above. After expression in the COS-7 cell line, soluble mutated receptors were partially purified on concanavalin A beads and then quantified by ELISA as indicated in Fig. 2 . Soluble receptors were consistently secreted at detectable concentrations in all mutants with the exception of mutants R2 and R8, both of which expressed soluble receptors at variable concentrations, which in occasion were below the detection limit of our ELISA. Similar results were also obtained by Western blot analysis (data not shown).
Proliferative Response of the TF-1 Cell Line to the Soluble Mutated CNTF Receptors ␣-It was described previously that gp130-and LIFR␤-bearing cell lines, but not CNTFR␣, could be rendered CNTF-sensitive by adding a soluble truncated form of the receptor ␣ subunit in the assay (Taga et al., 1992; Davis et al., 1993b . We previously reported that the LIF-sensitive TF-1 erythroleukemia cell line could proliferate in the presence of a combination of CNTF plus soluble CNTFR␣ (Davis et al., 1993b) . In the present experiments, the TF1 cells were grown with a fixed concentration of CNTF (5 ng/ml) and serial dilutions of mutated proteins. As shown in Fig. 3 , TF-1 cells could be induced to proliferate in the presence of the different mutants with the exception of the R3 mutant. Interestingly, this mutant was able to bind CNTF with a similar affinity constant as the wild type subunit (Fig. 1) but was unable to trigger cell proliferation, suggesting an impairment in the association with the two ␤ transducing subunits.
Induction of Haptoglobin Secretion in the HepG2 Hepatoma Cell Line by Soluble Mutated CNTF Receptors ␣-Similar experiments were carried out in HepG2 hepatoma cells known to co-express both gp130 and LIFR␤ and which can be induced to secrete acute phase proteins in response to the IL-6 family of cytokines (Baumann et al., 1993) . It was recently shown that haptoglobin production was increased by culturing this cell line in the presence of CNTF plus soluble CNTFR␣ (Saggio et al., 1995) . CNTFR␣ mutants were assessed for their induction of haptoglobin synthesis in HepG2 cells by culture with a limiting concentration of 10 ng/ml CNTF and 100 ng/ml of the different soluble mutated proteins. CNTF alone failed to increase spontaneous haptoglobin secretion, but its activity was potentiated by the addition of WT CNTFR␣ (Fig. 4) . As observed for the TF-1 cell line proliferative response, all the mutants with the exception of R3, were able to induce haptoglobin secretion, confirming the fact that this latter variant had lost its ability to recruit the signaling cascade leading to gene transcription.
Competitive Receptor Binding-Since Ala substitution for the residues Thr 268 and Asp 269 of CNTFR␣ resulted in a loss of R3 mutant bioactivity, we further analyzed the competitive potential of this mutant for binding of CNTF. 125 I-CNTF binding assays were performed in the presence or the absence of a molar excess of soluble CNTFR3␣ mutant. The experiments were carried out on the SK-N-MC neuroblastoma cell line, which expresses 500-1000 tripartite high affinity binding sites/ cell (K d ϭ 100 -400 pM) . Fig. 5A shows that addition of a 300-fold molar excess of soluble WT CNTFR␣ did not modulate the binding of CNTF to its tripartite surface receptor, indicating that the ␣ subunit was not a limiting element in the system. In contrast, the addition of an equivalent amount of the R3 variant to the assay led to a shift in the K d from 400 pM to 2 nM. This result demonstrates that the R3 receptor can exhibit an antagonist activity for CNTF binding, which is consistent with the concept that the observed affinity shift was due to the introduced mutation. No variation in the number of sites/cell was observed.
We further analyzed CNTFR3␣ interaction with gp130 and the LIFR␤ transduction complex. The experiments were conducted in the HepG2 cell line, which does not express the CNTFR␣ component (Saggio et al., 1995) . Fig. 5B shows that a weak but specific binding of 125 I-CNTF to the cells that was increased by the addition of exogenous soluble CNTFR␣ as previously reported . In contrast, substitution of wild type CNTFR␣ by R3 mutated receptor failed to increase the observed CNTF binding, suggesting an impairment of the ability of the R3 mutated receptor to interact with the transducing receptor complex.
Inhibition of CNTF-induced TF-1 Cell Line Proliferation by the R3 Mutant-
We examined the possibility that the R3 mutant may antagonize the proliferative TF1 cell line in response to CNTF plus soluble CNTFR␣. The assay was performed in the presence of fixed amounts of WT (30 ng/ml) and R3 (300 ng/ml) soluble receptors and increasing concentrations of CNTF. A 10-fold excess of R3 mutant led to a 100-fold inhibition of TF-1 cell proliferation induced by CNTF plus soluble CNTFR␣ (CNTF EC 50 ϭ 0.25 ng/ml, CNTF ϩ R3 EC 50 ϭ 30 ng/ml) ( Fig. 6A) . Moreover, 300 ng/ml mutated receptor was also able to inhibit the residual proliferative effect induced by CNTF alone on the TF1 cells, as shown in Fig. 6A . To assess the specificity of the observed inhibition, R3 was assayed by growing the TF1 cell line with IL-6, whose receptor contains an ␣ chain similar to CNTFR␣. The R3 mutant did not affect TF-1 cell proliferation in response to IL-6 ( Fig. 6B) . Similarly, activation of the OSM receptor, which also utilizes gp130 and LIF receptor ␤ as co-receptors, was not affected by exogenous addition of CNTFR3 (Fig. 6C) . Altogether, these results show that the R3 mutant specifically inhibits the proliferative response mediated by CNTF and its ␣ receptor component.
The R3 Mutant Receptor Inhibits Haptoglobin Synthesis Induced by CNTF in the HepG2 Cell Line-The soluble R3 variant of CNTFR␣ was also tested for its ability to antagonize gene transcription of haptoglobin in the HepG2 cell line. HepG2 cells were treated for 20 h with the indicated combinations of cytokines and soluble receptors. The haptoglobin content of the cultures was determined by ELISA. Fig. 7 shows that the R3 mutant was able to antagonize haptoglobin secretion induced by the addition of CNTF and 30 ng/ml WT CNTFR␣. Interestingly, a 2-fold excess of the mutated protein was able to neutralize 75% of wild type receptor bioactivity. No significant effect of the R3 mutant could be observed on haptoglobin secretion triggered by LIF (Fig. 7) , which reinforces the specificity of the neutralizing response.
The R3 Tyrosine Phosphorylation Induced by CNTF-CNTF binding to the membrane rapidly induces the recruitment and heterodimerization of gp130 and LIFR␤, which subsequently leads to activation of the Jak/Tyk tyrosine kinase family, which in turn phosphorylates tyrosine residues on both transducing receptor subunits . In order to determine whether the R3 mutant was able to antagonize immediate tyrosine phosphorylation events, HepG2 cells were stimulated with CNTF in the presence or absence of the soluble CNTFR␣ and the R3 mutated form of the subunit. Fig. 8 shows that soluble CNTFR␣ plus CNTF induced the recruitment and tyrosine phosphorylation of both gp130 and gp190-LIFR␤ components, whereas no signal could be detected when R3 was used instead of CNTFR␣ (Fig. 8A ). In agreement with the above data, induction of gp130/190 tyrosine phosphorylation observed in the presence of CNTF and soluble CNTFR␣ was strongly antagonized when a 10-fold excess of the R3 mutated receptor was introduced in the assay. The observed inhibition was specific for CNTF, since gp130/190 tyrosine phosphorylation induced by LIF was not affected by the R3 mutated form of soluble CNTFR␣ (Fig. 8B) .
These experiments demonstrate that the soluble R3 mutant behaves as a receptor antagonist specific for the CNTF response by neutralizing cell proliferation, gene transcription, and immediate phosphorylation events of the receptor transducing components. 
DISCUSSION
Based on the level of homology between the IL-6 receptor and CNTFR␣, a series of CNTF receptor mutants was generated by substituting Ala or Asn for the amino acids present in the E2 and F2 regions of the cytokine binding domain. Val 183 , located in the F1 region, whose equivalent amino acid in IL-6R␣ was previously reported to be important in the interaction with gp130, was also modified (Yawata et al., 1993; Salvati et al., 1995) .
In the present study we have identified two amino acids, Thr and Asp, respectively located at positions 268 and 269 of the CNTFR␣, that are implicated in the association of the ␣ bind-FIG. 6. Soluble CNTFR3␣ specifically antagonizes TF-1 cell proliferation in combination with CNTF and soluble CNTFR␣. A, TF-1 cell line proliferation was induced with increasing concentrations of CNTF in the absence of CNTFR␣ (Ⅺ) or in the presence of 300 ng/ml CNTFR3␣ alone (q), 30 ng/ml wild type CNTFR␣ (E), 30 ng/ml wild type CNTFR␣, and 300 ng/ml CNTFR3␣ (f). After a 72-h culture period, the cell proliferation was determined by [ 3 H]thymidine uptake. B, TF-1 cell proliferation was measured by growing the cells in the presence of increasing concentrations of IL-6 (E) or a combination of IL-6 and 300 ng/ml CNTFR3␣ (f). C, TF-1 cell proliferation was measured by growing the cells in the presence of increasing concentrations of OSM (Ⅺ) or a combination of OSM and 300 ng/ml CNTFR3␣ (q). All of the cultures were carried out in triplicate.
FIG. 7. Mutant CNTFR3␣ down-regulates haptoglobin synthesis induced by CNTF plus CNTFR␣ in the HepG2 cells.
HepG2 cells were stimulated in triplicate with 5 ng/ml CNTF or 10/ng/ml LIF and the indicated concentrations of wild type CNTFR␣ or CNTFR3␣. After a 20-h culture period, the culture supernatants were harvested, and their haptoglobin content was determined by ELISA.
FIG. 8. Mutant CNTFR3␣ specifically inhibits CNTF-dependent tyrosine phosphorylation of gp130 and gp190/LIFR␤. A,
HepG2 cells were stimulated for 10 min with 50 ng/ml CNTF and the indicated combinations of wild type CNTFR␣ (500 ng/ml) and CNTFR3␣ (5,000 ng/ml). gp130 and gp190-LIFR␤ were co-immunoprecitated by using the B-T6 anti-gp130 monoclonal antibody, and their level of tyrosine phosphorylation was analyzed after Western blotting. B, HepG2 cells were stimulated with 50 ng/ml LIF and the indicated combinations of CNTFR3␣ (5,000 ng/ml) or wild type CNTFR␣ (5,000 ng/ml). The tyrosine phosphorylation analysis was performed as in A.
ing subunit with the gp130-LIFR␤ transducing receptor subunits. Alanine substitution for these two residues resulted in the R3 mutated receptor phenotype. When expressed alone, R3 bound CNTF with an affinity constant identical to that detected for the wild type CNTFR␣ (Gearing et al., 1994; Wong et al., 1995; Robledo et al., 1996) . This result indicates that the mutated region belonging to the E2 strand found in cytokine receptors is not essential for cytokine binding. In addition to its loss of bioactivity in proliferative and gene transcription assays, the R3 CNTFR␣ variant can antagonize CNTF binding to its tripartite receptor, which fails to reassociate with the gp130-LIFR␤ heterocomplex when the neurotrophic factor is present. These observations suggest that the introduced mutation may interfere in the recognition between the ␣ component and the gp130-LIFR␤ transducing complex. However, this needs further confirmation by studying the direct binding of R3 to the transducing complex after this protein becomes available in a purified form. In addition, this reagent should allow discrimination between gp130 and LIFR␤ with regard to which of these components contacts positions 268 and 269 of CNTFR␣. We and other groups have previously reported a preferential association of the CNTF/CNTFR␣ heterocomplex with gp130 (Davis et al., 1993a; Stahl et al., 1993; Robledo et al., 1996) . In contrast, by using a different cell background for the transfection experiments, the alternative association was reported whereby CNTFR␣ preferentially binds to gp190-LIFR␤ (Gearing et al., 1994) .
The corresponding positions in IL-6R␣ were previously reported to be essential for IL-6R␣/gp130 interaction, and additional motifs were also identified in F1 and F2 strands (Yawata et al., 1993; Salvati et al., 1995) . The present study sustains the idea that F1 and F2 strands in CNTFR␣ are not essential for its association with the ␤ subunits. Another explanation could be ascribed to the nature of the mutations introduced in CNTFR␣. In IL-6R␣, Gly 285 and His 288 were substituted with nonhomologous amino acids. In the present study, the amino acids were substituted with Ala or Asn residues; hence, we can not rule out the possibility that a new insight into the ␣ receptor/ transducing component interactions may result from different amino acid substitutions.
In addition to its role as the ␣ binding components for IL-6 and CNTF, E2 strand had previously been shown to be implicated in the homodimerization of the GH binding protein, and a natural occurring mutant in the E2 strand (D152H), which was unable to homodimerize, was described (De Vos et al., 1992; Duquesnoy et al., 1994) . Site-directed mutagenesis in the common ␤ chain of GM-CSF, IL-3, and IL-5 receptors led to the identification of the same corresponding region (Woodcock et al., 1994) . These results suggest that the role of the E2 strand in the induction of the subunit dimerization phenomenon might be a common rule for cytokine receptors.
A binding subunit for IL-11 displaying a similar homology level to IL-6R␣ and CNTFR␣ was recently isolated in the mouse and human (Hilton et al., 1994; Cherel et al., 1995) . Since gp130 is also involved in the transducing machinery of IL-11, we aligned the amino acid sequences of CNTFR␣ and IL-11R␣. The sequence comparison shows a conservation of the identified Thr and Asp amino acids in the corresponding area of the IL-11R␣. This suggests that IL-11R␣ interacts with gp130 in a similar manner.
We further analyzed the antagonist potential of the R3 mutant for the CNTF response. The experiments show a specific inhibition of the proliferative response of TF1 cells when triggered by a combination of CNTF plus WT CNTFR␣ and the addition of a 10-fold excess of R3 variant. Moreover, the R3 mutant also antagonizes the induction of tyrosine phosphoryl-ation in the gp130-gp190 heterocomplex, as well as the transduction cascade leading to haptoglobin synthesis.
Experimental CNTFR␣ gene inactivation in mice induces a profound anomaly in motoneuron development, resulting in perinatal death (DeChiara et al., 1995) . In contrast, CNTF deficiency was reported to only mildly affect mouse behavior and physiology (Masu et al., 1993) . Similarly, no detectable disease has been associated with a null homozygous mutation observed in 2% of the human population. Altogether these studies support the concept that an alternate ligand for CNTFR␣ may exist. Since such a molecule has not yet been reported, we do not know whether the R3 mutated receptor subunit will be able to interfere with this potentially new cytokine, and it will of interest to determine whether the R3 subunit can discriminate between the two ligand responses. The production of transgenic mice overexpressing the R3 mutant subunit followed by analysis of the resulting phenotype should partially answer this question.
